IsoRay completes merger with Viewpoint Molecular Targeting

2020 08 20 17 37 8876 Business Handshake Man 400

Medical isotope developer IsoRay has completed its merger with Viewpoint Molecular Targeting. The deal closed on February 3.

The two firms plan to focus on developing targeted cancer treatment using radiation, radiopharmaceuticals, and imaging. Viewpoint Molecular chief executive officer Thijs Spoor will be CEO of the newly combined company, while outgoing IsoRay CEO Lori Woods has been named chair of the board of directors.

Page 1 of 436
Next Page